Hidradenitis Suppurativa

New results from a phase-3 study demonstrating the effect of Humira (adalimumab, AbbVie) in treating moderate-to-severe hidradenitis suppurativa (HS) may lead to worldwide regulatory filings for expanded use of the drug.

Hidradenitis suppurativa (HS) is a challenging disease to treat; however, a better understanding of the disease and continued research has led to more clear-cut therapeutic options, according to an expert who spoke at the North American Clinical Dermatologic Society meeting.

There is a misconception that people with skin of color are not at risk of skin cancer, and dermatologists are responsible for better educating themselves and their patients about this danger, says an expert who spoke at the 72nd Annual Meeting of the American Academy of Dermatology.

A variety of treatments aside from antibiotics have shown some efficacy in managing hidradenitis suppurativa (HS), according to a clinician speaking at the Dermatology Update 2013 meeting.

Adalimumab (Humira, AbbVie) is demonstrating effectiveness in early trials for the treatment of hidradenitis suppurativa, a condition that as of yet has no approved treatment.